International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

International Assets Investment Management LLC grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 29,580.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 10,388 shares of the biopharmaceutical company's stock after acquiring an additional 10,353 shares during the period. International Assets Investment Management LLC's holdings in Ultragenyx Pharmaceutical were worth $577,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Ultragenyx Pharmaceutical by 513.8% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company's stock worth $23,677,000 after purchasing an additional 424,476 shares during the last quarter. Clearbridge Investments LLC increased its position in shares of Ultragenyx Pharmaceutical by 0.7% during the 1st quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company's stock worth $112,096,000 after purchasing an additional 17,362 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Ultragenyx Pharmaceutical by 3.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company's stock worth $166,632,000 after acquiring an additional 120,175 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at about $1,074,000. Finally, Vanguard Group Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 0.3% during the first quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company's stock valued at $406,203,000 after acquiring an additional 26,575 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Howard Horn sold 7,465 shares of the company's stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the transaction, the chief executive officer now owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,556 shares of company stock worth $1,515,967. Company insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

RARE traded down $1.66 during midday trading on Wednesday, hitting $50.52. The stock had a trading volume of 1,576,950 shares, compared to its average volume of 781,603. Ultragenyx Pharmaceutical Inc. has a 1 year low of $34.06 and a 1 year high of $60.37. The business has a fifty day moving average of $55.32 and a 200 day moving average of $48.11. The company has a market cap of $4.66 billion, a P/E ratio of -6.92 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating analysts' consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million for the quarter, compared to analysts' expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company's quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.23) EPS. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.29 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on RARE. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an "overweight" rating for the company in a report on Monday, August 5th. Royal Bank of Canada restated an "outperform" rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday. The Goldman Sachs Group upped their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Wells Fargo & Company raised their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Finally, Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $109.00 to $121.00 and gave the stock a "buy" rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average target price of $86.69.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.